NVS

Novartis (NVS)

Novartis AG

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NYSE:NVS

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/09/16	21 : 44	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NYSE:NVS	Novartis AG
2024/09/16	21 : 12	Edgar (US Regulatory)	Form F-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers	NYSE:NVS	Novartis AG
2024/09/16	19 : 03	IH Market News	Intel Secures $3.5 Billion Subsidy, Stellantis Backs EU Emissions Targets, BP and Apollo Reach $1 Billion Deal	NYSE:NVS	Novartis AG
2024/09/11	07 : 53	AllPennyStocks.com	Junior Biotech Utilizes AI To Shorten Drug Discovery Timelines, Ultimately Saving Lives	NYSE:NVS	Novartis AG
2024/09/05	21 : 00	GlobeNewswire Inc.	Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14	NYSE:NVS	Novartis AG
2024/08/29	01 : 16	Business Wire	Lindy Biosciences stringe un accordo di licenza e collaborazione con Novartis per la somministrazione innovativa di farmaci multitarget	NYSE:NVS	Novartis AG
2024/08/29	01 : 07	Business Wire	Lindy Biosciences conclut un accord de licence et de collaboration avec Novartis pour l’innovation en matière d’administration de médicaments à cibles multiples	NYSE:NVS	Novartis AG
2024/08/29	01 : 06	Business Wire	Lindy Biosciences schließt Lizenzierungs- und Kooperationsvereinbarung mit Novartis für Wirkstoffabgabeinnovation für mehrere Zielmoleküle ab	NYSE:NVS	Novartis AG
2024/08/28	19 : 58	Business Wire	Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation	NYSE:NVS	Novartis AG
2024/08/26	21 : 58	IH Market News	IBM Closes China Research Division, Uber Fined $324M, Starliner to Return Without Astronauts	NYSE:NVS	Novartis AG
2024/08/16	05 : 30	Edgar (US Regulatory)	Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]	NYSE:NVS	Novartis AG
2024/08/14	05 : 31	Edgar (US Regulatory)	Form SC TO-T/A - Tender offer statement by Third Party: [Amend]	NYSE:NVS	Novartis AG
2024/08/13	04 : 30	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NYSE:NVS	Novartis AG
2024/08/08	08 : 38	PR Newswire (US)	Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)	NYSE:NVS	Novartis AG
2024/08/06	18 : 44	IH Market News	Google Faces Antitrust Ruling; SunPower Files for Bankruptcy and Business Sale – Latest Business News	NYSE:NVS	Novartis AG
2024/08/03	05 : 30	Edgar (US Regulatory)	Form SC TO-T/A - Tender offer statement by Third Party: [Amend]	NYSE:NVS	Novartis AG
2024/08/02	05 : 30	Edgar (US Regulatory)	Form SC TO-T/A - Tender offer statement by Third Party: [Amend]	NYSE:NVS	Novartis AG
2024/08/01	05 : 30	Edgar (US Regulatory)	Form SC TO-T/A - Tender offer statement by Third Party: [Amend]	NYSE:NVS	Novartis AG
2024/07/31	05 : 30	Edgar (US Regulatory)	Form SC TO-T/A - Tender offer statement by Third Party: [Amend]	NYSE:NVS	Novartis AG
2024/07/30	20 : 00	GlobeNewswire Inc.	Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update	NYSE:NVS	Novartis AG
2024/07/30	05 : 30	Edgar (US Regulatory)	Form SC TO-T/A - Tender offer statement by Third Party: [Amend]	NYSE:NVS	Novartis AG
2024/07/26	05 : 30	Edgar (US Regulatory)	Form SC TO-T/A - Tender offer statement by Third Party: [Amend]	NYSE:NVS	Novartis AG
2024/07/19	05 : 30	Edgar (US Regulatory)	Form SC TO-T/A - Tender offer statement by Third Party: [Amend]	NYSE:NVS	Novartis AG
2024/07/18	19 : 09	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NYSE:NVS	Novartis AG
2024/07/18	18 : 53	IH Market News	TSMC Net Profit Hits $7.6B; Nokia Sees 32% Decline in Operating Profit; Novartis Boosts Outlook After Profit Surge	NYSE:NVS	Novartis AG
2024/07/12	05 : 30	Edgar (US Regulatory)	Form SC TO-T/A - Tender offer statement by Third Party: [Amend]	NYSE:NVS	Novartis AG
2024/06/18	05 : 30	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NYSE:NVS	Novartis AG
2024/05/25	19 : 15	PR Newswire (US)	Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio	NYSE:NVS	Novartis AG
2024/05/25	19 : 00	PR Newswire (US)	Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo	NYSE:NVS	Novartis AG
2024/05/25	05 : 31	Edgar (US Regulatory)	Form SC TO-T/A - Tender offer statement by Third Party: [Amend]	NYSE:NVS	Novartis AG